Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.52 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | REN | P00797 | 1/20 | 0.45 |
| ▸ | MVD | P53602 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5495836 | 1.00 | ACE (0.52) | ACEFKBP1ARAB9AALDH1A1REN | |
| SCHEMBL6877311 | 1.00 | ACE (0.52) | ACEFKBP1ARAB9AALDH1A1REN | |
| SCHEMBL5496862 | 0.94 | FKBP1A (0.53) | ACEFKBP1AALDH1A1KDM4EHPGD | |
| SCHEMBL5496855 | 0.94 | FKBP1A (0.53) | ACEFKBP1AALDH1A1KDM4EHPGD | |
| SCHEMBL6883997 | 0.94 | FKBP1A (0.53) | ACEFKBP1AALDH1A1KDM4EHPGD | |
| SCHEMBL7048968 | 0.89 | ACE (0.50) | ACEFKBP1ARAB9ARENACE2 | |
| SCHEMBL8626274 | 0.86 | FKBP1A (0.56) | FKBP1AALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL11618236 | 0.86 | ACE (0.55) | ACERAB9AALDH1A1RENMVD | |
| Miridesap SCHEMBL1537496 | 0.85 | ACE (0.68) | ACERENMVD | |
| Miridesap SCHEMBL1685022 | 0.85 | ACE (0.68) | ACERENMVD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1743884-A1 | Progrugs to d-prolines | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-17 | — | — | EP | disclosed |
| US-6903129-B2 | D-proline prodrugs | HOFFMAN-LA ROCHE INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-20030134891-A1 | New D-proline prodrugs | PENTRAXIN THERAPEUTICS LTD. (GB) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134891-A1 | New D-proline prodrugs | PCNP, PREP, APP | ACE 330/4885FKBP1A 203/4885RAB9A 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.